litlas
ログインアカウント作成

Alan Sandler

1995–2020 年に発表

44
論文数
41,225
被引用数
44
h 指数
44
i10 指数

被引用数

Alan Sandler の年別被引用数1997 年: 被引用 1 件1999 年: 被引用 3 件2000 年: 被引用 7 件2001 年: 被引用 7 件2002 年: 被引用 33 件2003 年: 被引用 46 件2004 年: 被引用 118 件2005 年: 被引用 215 件2006 年: 被引用 210 件2007 年: 被引用 262 件2008 年: 被引用 251 件2009 年: 被引用 319 件2010 年: 被引用 281 件2011 年: 被引用 246 件2012 年: 被引用 211 件2013 年: 被引用 196 件2014 年: 被引用 156 件2015 年: 被引用 148 件2016 年: 被引用 200 件2017 年: 被引用 336 件2018 年: 被引用 436 件2019 年: 被引用 1,688 件2020 年: 被引用 2,065 件2021 年: 被引用 1,999 件2022 年: 被引用 1,441 件2023 年: 被引用 979 件2024 年: 被引用 1,312 件2025 年: 被引用 539 件2026 年: 被引用 6 件1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,833 件、この内訳の 23.8%中国: 引用元論文 2,547 件、この内訳の 15.8%日本: 引用元論文 968 件、この内訳の 6%イタリア: 引用元論文 877 件、この内訳の 5.4%フランス: 引用元論文 754 件、この内訳の 4.7%イギリス: 引用元論文 754 件、この内訳の 4.7%ドイツ: 引用元論文 667 件、この内訳の 4.1%スペイン: 引用元論文 603 件、この内訳の 3.7%カナダ: 引用元論文 490 件、この内訳の 3%韓国: 引用元論文 407 件、この内訳の 2.5%スイス: 引用元論文 382 件、この内訳の 2.4%オーストラリア: 引用元論文 371 件、この内訳の 2.3%
0%23.8%その他 21.6%

機関

分野

  • Medicine78.7%
  • Biochemistry, Genetics and Molecular Biology14.6%
  • Immunology and Microbiology3.4%
  • Engineering0.6%
  • Materials Science0.5%
  • Mathematics0.5%
  • その他1.7%

トピック

  • Cancer Immunotherapy and Biomarkers15.2%
  • Lung Cancer Treatments and Mutations11.9%
  • Lung Cancer Research Studies8.9%
  • Lung Cancer Diagnosis and Treatment4.9%
  • Immunotherapy and Immune Responses3%
  • Cancer Genomics and Diagnostics2.9%
  • その他53.2%

共著者

全論文

検索で開く
  1. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

    著者: Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J. Hochmair, Florian Huemer, György Losonczy, Melissa L. Johnson, Makoto Nishio, Martin Reck, Tony Mok, Sivuonthanh Lam, David S. Shames, Juan Liu, Beiying Ding, Ariel López-Chávez, Fairooz F. Kabbinavar, Wei Lin, Alan Sandler, Stephen V. Liu - New England Journal of Medicine 2018 被引用: 3,507

  2. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

    著者: Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel López-Chávez, Alan Sandler, Martin Reck - New England Journal of Medicine 2018 被引用: 3,753

  3. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

    著者: Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara - The Lancet 2016 被引用: 4,780

  4. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

    著者: Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andrić, Sarayut Lucien Geater, Mustafa Özgüroğlu, Wei Zou, Alan Sandler, Ida Enquist, Kimberly M. Komatsubara, Yu Deng, Hiroshi Kuriki, Xiaohui Wen, Mark L. McCleland, Simonetta Mocci, Jacek Jassem, David R. Spigel - New England Journal of Medicine 2020 被引用: 1,691

  5. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

    著者: Howard West, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Henry Jacob Conter, Hans‐Georg Kopp, Davey B. Daniel, Steven McCune, Tarek Mekhail, Alona Zer, Niels Reinmuth, Ahad A. Sadiq, Alan Sandler, Wei Lin, Tania Ochi Lohmann, Venice Archer, Lijia Wang, Marcin Kowanetz, Federico Cappuzzo - The Lancet Oncology 2019 被引用: 1,681

  6. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

    著者: Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Julien Mazières, Keunchil Park, David C. Smith, Á. Artal, C. Lewanski, Fadi Braiteh, Daniel Waterkamp, Pei He, Wei Zou, Daniel S. Chen, Jing Yi, Alan Sandler, Achim Rittmeyer - The Lancet 2016 被引用: 2,803

  7. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

    著者: David R. Gandara, Sarah Paul, Marcin Kowanetz, Erica Schleifman, Wei Zou, Yan Li, Achim Rittmeyer, Louis Fehrenbacher, Geoff Otto, Christine M. Malboeuf, Daniel S. Lieber, Doron Lipson, Jacob Silterra, Lukas C. Amler, Todd Riehl, Craig Cummings, Priti S. Hegde, Alan Sandler, Marcus Ballinger, David Fabrizio, Tony Mok, David S. Shames - Nature Medicine 2018 被引用: 1,195

  8. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

    著者: Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodríguez‐Abreu, Maen Hussein, Ross A. Soo, Henry Jacob Conter, Toshiyuki Kozuki, Kuan-Chieh Huang, Vilma Graupner, Shawn W. Sun, Tien Hoang, Helen Jessop, Mark L. McCleland, Marcus Ballinger, Alan Sandler, Mark A. Socinski - Journal of Thoracic Oncology 2020 被引用: 607

  9. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

    著者: Alan Sandler, Robert J. Gray, Michael C. Perry, Julie R. Brahmer, Joan H. Schiller, Afshin Dowlati, Rogério Lilenbaum, David H. Johnson - New England Journal of Medicine 2006 被引用: 5,778

  10. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

    著者: Joan H. Schiller, David Harrington, Chandra P. Belani, Corey J. Langer, Alan Sandler, James E. Krook, Junming Zhu, David H. Johnson - New England Journal of Medicine 2002 被引用: 4,984

  11. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

    著者: Solange Peters, Scott Gettinger, Melissa L. Johnson, Pasi A. Jänne, Marina Chiara Garassino, Daniel C. Christoph, Chee‐Keong Toh, Naiyer A. Rizvi, Jamie E. Chaft, Enric Carcereny, Jyoti D. Patel, Laura Q.M. Chow, Marianna Koczywas, Cheryl Ho, Martin Früh, Michel M. van den Heuvel, J. Rothenstein, Martin Reck, Luis Paz‐Ares, Frances A. Shepherd, Takayasu Kurata, Zhengrong Li, Jiaheng Qiu, Marcin Kowanetz, Simonetta Mocci, Geetha Shankar, Alan Sandler, Enriqueta Felip - Journal of Clinical Oncology 2017 被引用: 419

  12. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

    著者: Louis Fehrenbacher, Joachim von Pawel, Keunchil Park, Achim Rittmeyer, David R. Gandara, Santiago Ponce Aix, Ji‐Youn Han, Shirish M. Gadgeel, Toyoaki Hida, Diego Cortinovis, Manuel Cobo, Dariusz M. Kowalski, Filippo de Marinis, Mayank Gandhi, Bradford J. Danner, Christina Matheny, Marcin Kowanetz, Pei He, Federico Felizzi, Hina Patel, Alan Sandler, Marcus Ballinger, Fabrice Barlési - Journal of Thoracic Oncology 2018 被引用: 261

  13. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

    著者: Marcin Kowanetz, Wei Zou, Scott Gettinger, Hartmut Koeppen, Mark Kockx, Peter Schmid, Edward E. Kadel, Ignacio I. Wistuba, Jamie E. Chaft, Naiyer A. Rizvi, David R. Spigel, Alexander I. Spira, Fred R. Hirsch, Victor Cohen, Dustin Smith, Zach Boyd, Natasha Miley, Susan Flynn, Vincent Lévêque, David S. Shames, Marcus Ballinger, Simonetta Mocci, Geetha Shankar, Roel Funke, Garret M. Hampton, Alan Sandler, Lukas C. Amler, Ira Mellman, Daniel S. Chen, Priti S. Hegde - National Academy of Sciences, Proceedings of the National Academy of Sciences 2018 被引用: 239

  14. Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

    著者: David R. Gandara, Joachim von Pawel, Julien Mazières, Richard Sullivan, Åslaug Helland, Ji‐Youn Han, Santiago Ponce Aix, Achim Rittmeyer, Fabrice Barlési, Toshio Kubo, Keunchil Park, Jerome H. Goldschmidt, Mayank Gandhi, Cindy Yun, Wei Yu, Christina Matheny, Pei He, Alan Sandler, Marcus Ballinger, Louis Fehrenbacher - Journal of Thoracic Oncology 2018 被引用: 163

  15. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study

    著者: Shirish M. Gadgeel, Rimas V. Lukas, Jerome H. Goldschmidt, Paul Conkling, Keunchil Park, Diego Cortinovis, Filippo de Marinis, Achim Rittmeyer, Jyoti D. Patel, Joachim von Pawel, Carol O’Hear, Catherine Lai, Sylvia Hu, Marcus Ballinger, Alan Sandler, Mayank Gandhi, L. Fehrenbacher - Lung Cancer 2018 被引用: 172

  16. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

    著者: Mark G. Kris, Ronald B. Natale, Roy S. Herbst, T. J. Lynch, Diane Prager, Chandra P. Belani, Joan H. Schiller, Karen Kelly, H. Spiridonidis, Alan Sandler, Kathy S. Albain, David Cella, Michael Wolf, Steven D. Averbuch, Judith Ochs, Andrea Kay - JAMA 2003 被引用: 2,538

  17. Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

    著者: Nasser H. Hanna, Paul A. Bunn, Corey J. Langer, Lawrence H. Einhorn, Troy H. Guthrie, Thaddeus Beck, Rafat Ansari, Peter Ellis, Michael Byrne, Mark E. Morrison, Subramanian Hariharan, Benjamin Wang, Alan Sandler - Journal of Clinical Oncology 2006 被引用: 678

  18. Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial

    著者: Ariel López-Chávez, Anish Thomas, Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan J. Kelly, Corey Allan Carter, Udayan Guha, Keith Killian, Christopher Lau, Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer, Christopher L. Corless, Alan Sandler, Carol Beadling, Andrea Warrick, David J. Liewehr, Seth M. Steinberg, Arlene Berman, Austin Doyle, Éva Szabó, Yisong Wang, Giuseppe Giaccone - Journal of Clinical Oncology 2015 被引用: 235

  19. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

    著者: David R. Spigel, Jamie E. Chaft, Scott Gettinger, Bo H. Chao, Luc Dirix, Peter Schmid, Laura Q.M. Chow, Rodney J. Hicks, Larry Leon, Jill Fredrickson, Marcin Kowanetz, Alan Sandler, Roel Funke, Naiyer A. Rizvi - Journal of Thoracic Oncology 2018 被引用: 172

  20. Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models

    著者: Jeffrey M. Albert, Carolyn Cao, Kwang Woon Kim, Christopher D. Willey, Ling Geng, Dakai Xiao, Hong Wang, Alan Sandler, David H. Johnson, A. D. Colevas, Jennifer A. Low, Mace L. Rothenberg, Bo Lü - Clinical Cancer Research 2007 被引用: 265

  21. A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy

    著者: Alan Sandler, Michael A. Gordon, Dinesh P. de Alwis, Isabelle Pouliquen, Lisa Green, Phil Marder, Ajai K. Chaudhary, Karen Fife, Linda A. Battiato, Christopher Sweeney, Christopher Jordan, Michael Burgess, Christopher A. Slapak - Clinical Cancer Research 2004 被引用: 151

  22. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non–Small-cell Lung Cancer

    著者: Rodolfo Bordoni, Fortunato Ciardiello, Joachim von Pawel, Diego Cortinovis, Thomas Karagiannis, Marcus Ballinger, Alan Sandler, Wei Yu, Pei He, Christina Matheny, Federico Felizzi, Achim Rittmeyer - Clinical Lung Cancer 2018 被引用: 77

  23. TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

    著者: Roy S. Herbst, Diane Prager, Róbert Hermann, L. Fehrenbacher, Bruce E. Johnson, Alan Sandler, Mark G. Kris, Hai T. Tran, Pam Klein, Xin Li, David A. Ramies, David H. Johnson, Vincent A. Miller - Journal of Clinical Oncology 2005 被引用: 1,497

  24. Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs

    著者: Gregory A. Otterson, Miguel A. Villalona‐Calero, Sunil Sharma, Mark G. Kris, A. R. Imondi, Mirjam C. Gerber, Dorothy A. White, Mark J. Ratain, Joan H. Schiller, Alan Sandler, Michael Kraut, Sridhar Mani, John R. Murren - Clinical Cancer Research 2007 被引用: 131